These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6478397)

  • 1. Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An extramural analysis.
    Corle DK; Sears ME; Olson KB
    Cancer; 1984 Oct; 54(8):1554-61. PubMed ID: 6478397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer?
    Lippman ME; Allegra JC
    Recent Results Cancer Res; 1980; 71():155-61. PubMed ID: 7367728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
    J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study.
    Rosner D; Lane WW; Nemoto T
    Cancer; 1989 Jul; 64(1):6-15. PubMed ID: 2731120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
    Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
    J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential hormone therapy for advanced breast cancer.
    Von Roenn JH; Bonomi PD; Gale M; Anderson KM; Wolter JM; Economou SG
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):38-43. PubMed ID: 3368799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
    Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
    Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
    Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
    J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
    Loprinzi CL; Tormey DC; Rasmussen P; Falkson G; Davis TE; Falkson HC; Chang AY
    J Clin Oncol; 1986 Jan; 4(1):46-56. PubMed ID: 3510282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Falkson G; Gelman RS; Tormey DC; Cummings FJ; Carbone PP; Falkson HC
    Cancer; 1985 Jul; 56(2):219-24. PubMed ID: 3839157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
    Zambetti M; Mansutti M; Gomez P; Lluch A; Dittrich C; Zamagni C; Ciruelos E; Pavesi L; Semiglazov V; De Benedictis E; Gaion F; Bari M; Morandi P; Valagussa P; Luca G
    Breast Cancer Res Treat; 2012 Apr; 132(3):843-51. PubMed ID: 21750964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.